Call it a case of hindsight. Abraxis Bioscience and AstraZeneca are poised to end their two-year marketing partnership on the breast cancer treatment Abraxane, which cost Astra $200 million back in ...

Celgene Corp, producers of blood cancer drugs Thalomid and Revlimid, has agreed to acquire Abraxis BioScience for $2.9 billion in cash and stock. Celgene Corp, producers of blood cancer drugs Thalomid ...

RALEIGH - Abraxis Bioscience Inc.'s Raleigh office could benefit from a Los Angeles company's plans to separate into two publicly traded companies and recapitalize both concerns. Company officials say ...

New entity, Abraxis Health, will focus on personalized medicine. Abraxis BioScience decided to spin out Abraxis Health, which will focus on evidence-based, personalized healthcare. Abraxis BioScience ...

Celgene to Acquire Abraxis BioScience Inc. ABRAXANE(R) Approved for Second-Line Use in Metastatic Breast Cancer, Establishes Celgene in Solid Tumors Complementing Its Leadership Position in Blood ...

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that Leon (Lonnie) O. Moulder, Jr., has been appointed Vice Chairman, ...

Abraxis will retain all responsibility for clinical and regulatory development, manufacture and distribution of the product. In addition to the sales force already established at Abraxis, AstraZeneca ...

Abraxis is making an investment of $7 million and will pay milestones and revenues related to services provided. Abraxis BioScience and ProMetic Life Sciences are allying to develop four drugs based ...

The National Comprehensive Cancer Network (NCCN), Abraxis BioScience, and AstraZeneca has announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of ...

Shares of Abraxis BioScience on Wednesday shot higher by 30% after the drugmaker announced that its lung cancer treatment Abraxane passed a successful late-stage test. The Los Angeles company said the ...

The split between AstraZeneca and Abraxis over their copromotion of cancer drug Abraxane was expected among some Abraxis reps since August of this year. Now it's official. The end of the agreement ...